Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interleukin-8 (IL-8), also known as CXCL8, is a chemokine belonging to the CXC chemokine family. It is a small soluble protein produced by various cell types, including macrophages, epithelial cells, endothelial cells, and tumor cells. IL-8 is a key mediator of the inflammatory response, primarily functioning as a potent chemoattractant for neutrophils, guiding them to sites of infection or inflammation. It also stimulates phagocytosis and is a proangiogenic cytokine, promoting the formation of new blood vessels. IL-8 mediates its biological effects by binding to and activating two G protein-coupled receptors, CXCR1 and CXCR2, expressed on the surface of neutrophils and other immune cells. This binding initiates intracellular signaling cascades, including the activation of ERK1/2, STAT, Smad, and AKT pathways, leading to neutrophil activation, migration, and accumulation, as well as promoting angiogenesis, cell proliferation, and metastasis in cancer. Dysregulated IL-8 activity is implicated in a variety of inflammatory diseases and cancers, making it a significant target for therapeutic development, with approaches including IL-8 inhibitors and agonists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-8.